Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Financial Statements Detail (Tables)

v3.21.1
Condensed Consolidated Financial Statements Detail (Tables)
3 Months Ended
Mar. 31, 2021
Condensed Consolidated Financial Statements Detail [Abstract]  
Accrued and Other Liabilities

Accrued and other liabilities consisted of the following (in thousands):

March 31, 

December 31, 

    

2021

    

2020

Accrued legal and accounting fees

$

949

$

351

Accrued incentive compensation

231

71

Accrued payroll and other benefits

 

111

 

136

Other

50

40

Interest payable

 

35

 

44

Total

$

1,376

$

642

Reconciliation of Numerator and Denominator Used in Calculation of Basic and Diluted Net (Loss) per Share Available to Common Stockholders

The following is a reconciliation of the numerator (net loss) and the denominator (number of shares) used in the calculation of basic and diluted net loss per share attributable to common stockholders (in thousands, except per share amounts):

Three Months Ended March 31, 

    

2021

    

2020

Numerator

 

  

 

  

Net loss

$

(7,373)

$

(4,758)

Less: Series A accumulated dividends

 

(530)

Net loss available to common stockholders, basic and diluted

$

(7,903)

$

(4,758)

 

 

Denominator

 

 

Weighted average shares used in computing basic and diluted net loss per share available to common stockholders

 

11,240

 

9,761

Basic and diluted net loss per share of common stock

$

(0.70)

$

(0.49)

Outstanding Securities Considered Anti-Dilutive

The following table shows the weighted-average outstanding securities considered anti-dilutive and therefore excluded from the computation of diluted net loss per share attributable to common stockholders (in thousands):

Three Months Ended March 31, 

    

2021

    

2020

Convertible preferred stock

5,003

6,256

Common stock options

 

277

532

Warrants for common stock

 

5

15

Total

 

5,285

 

6,803